HighTide Therapeutics Releases Phase 2a MASH Study Findings at International Liver Congress 2024
Tuesday, 4 June 2024, 23:20
HighTide Therapeutics Phase 2a MASH Study Results
The recent presentation at the 2024 International Liver Congress unveiled the latest insights from HighTide Therapeutics regarding the Phase 2a MASH Study. The findings underscored the efficacy and safety of Berberine Ursodeoxycholate (H, further enhancing the understanding of its potential benefits in liver-related conditions.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.